Cargando…
Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients
OBJECTIVE: The purpose of this study was to examine the levels of cerebrospinal fluid (CSF) apolipoprotein E (apoE) species in Alzheimer’s disease (AD) patients. METHODS: We analyzed two CSF cohorts of AD and control individuals expressing different APOE genotypes. Moreover, CSF samples from the TgF...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628034/ https://www.ncbi.nlm.nih.gov/pubmed/36324176 http://dx.doi.org/10.1186/s13195-022-01108-2 |
_version_ | 1784823105719369728 |
---|---|
author | Lennol, Matthew Paul Sánchez-Domínguez, Irene Cuchillo-Ibañez, Inmaculada Camporesi, Elena Brinkmalm, Gunnar Alcolea, Daniel Fortea, Juan Lleó, Alberto Soria, Guadalupe Aguado, Fernando Zetterberg, Henrik Blennow, Kaj Sáez-Valero, Javier |
author_facet | Lennol, Matthew Paul Sánchez-Domínguez, Irene Cuchillo-Ibañez, Inmaculada Camporesi, Elena Brinkmalm, Gunnar Alcolea, Daniel Fortea, Juan Lleó, Alberto Soria, Guadalupe Aguado, Fernando Zetterberg, Henrik Blennow, Kaj Sáez-Valero, Javier |
author_sort | Lennol, Matthew Paul |
collection | PubMed |
description | OBJECTIVE: The purpose of this study was to examine the levels of cerebrospinal fluid (CSF) apolipoprotein E (apoE) species in Alzheimer’s disease (AD) patients. METHODS: We analyzed two CSF cohorts of AD and control individuals expressing different APOE genotypes. Moreover, CSF samples from the TgF344-AD rat model were included. Samples were run in native- and SDS-PAGE under reducing or non-reducing conditions (with or without β-mercaptoethanol). Immunoprecipitation combined with mass spectrometry or western blotting analyses served to assess the identity of apoE complexes. RESULTS: In TgF344-AD rats expressing a unique apoE variant resembling human apoE4, a ~35-kDa apoE monomer was identified, increasing at 16.5 months compared with wild-types. In humans, apoE isoforms form disulfide-linked dimers in CSF, except apoE4, which lacks a cysteine residue. Thus, controls showed a decrease in the apoE dimer/monomer quotient in the APOE ε3/ε4 group compared with ε3/ε3 by native electrophoresis. A major contribution of dimers was found in APOE ε3/ε4 AD cases, and, unexpectedly, dimers were also found in ε4/ε4 AD cases. Under reducing conditions, two apoE monomeric glycoforms at 36 kDa and at 34 kDa were found in all human samples. In AD patients, the amount of the 34-kDa species increased, while the 36-kDa/34-kDa quotient was lower compared with controls. Interestingly, under reducing conditions, a ~100-kDa apoE complex, the identity of which was confirmed by mass spectrometry, also appeared in human AD individuals across all APOE genotypes, suggesting the occurrence of aberrantly resistant apoE aggregates. A second independent cohort of CSF samples validated these results. CONCLUSION: These results indicate that despite the increase in total apoE content the apoE protein is altered in AD CSF, suggesting that function may be compromised. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-022-01108-2. |
format | Online Article Text |
id | pubmed-9628034 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-96280342022-11-03 Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients Lennol, Matthew Paul Sánchez-Domínguez, Irene Cuchillo-Ibañez, Inmaculada Camporesi, Elena Brinkmalm, Gunnar Alcolea, Daniel Fortea, Juan Lleó, Alberto Soria, Guadalupe Aguado, Fernando Zetterberg, Henrik Blennow, Kaj Sáez-Valero, Javier Alzheimers Res Ther Research OBJECTIVE: The purpose of this study was to examine the levels of cerebrospinal fluid (CSF) apolipoprotein E (apoE) species in Alzheimer’s disease (AD) patients. METHODS: We analyzed two CSF cohorts of AD and control individuals expressing different APOE genotypes. Moreover, CSF samples from the TgF344-AD rat model were included. Samples were run in native- and SDS-PAGE under reducing or non-reducing conditions (with or without β-mercaptoethanol). Immunoprecipitation combined with mass spectrometry or western blotting analyses served to assess the identity of apoE complexes. RESULTS: In TgF344-AD rats expressing a unique apoE variant resembling human apoE4, a ~35-kDa apoE monomer was identified, increasing at 16.5 months compared with wild-types. In humans, apoE isoforms form disulfide-linked dimers in CSF, except apoE4, which lacks a cysteine residue. Thus, controls showed a decrease in the apoE dimer/monomer quotient in the APOE ε3/ε4 group compared with ε3/ε3 by native electrophoresis. A major contribution of dimers was found in APOE ε3/ε4 AD cases, and, unexpectedly, dimers were also found in ε4/ε4 AD cases. Under reducing conditions, two apoE monomeric glycoforms at 36 kDa and at 34 kDa were found in all human samples. In AD patients, the amount of the 34-kDa species increased, while the 36-kDa/34-kDa quotient was lower compared with controls. Interestingly, under reducing conditions, a ~100-kDa apoE complex, the identity of which was confirmed by mass spectrometry, also appeared in human AD individuals across all APOE genotypes, suggesting the occurrence of aberrantly resistant apoE aggregates. A second independent cohort of CSF samples validated these results. CONCLUSION: These results indicate that despite the increase in total apoE content the apoE protein is altered in AD CSF, suggesting that function may be compromised. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-022-01108-2. BioMed Central 2022-11-02 /pmc/articles/PMC9628034/ /pubmed/36324176 http://dx.doi.org/10.1186/s13195-022-01108-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Lennol, Matthew Paul Sánchez-Domínguez, Irene Cuchillo-Ibañez, Inmaculada Camporesi, Elena Brinkmalm, Gunnar Alcolea, Daniel Fortea, Juan Lleó, Alberto Soria, Guadalupe Aguado, Fernando Zetterberg, Henrik Blennow, Kaj Sáez-Valero, Javier Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients |
title | Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients |
title_full | Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients |
title_fullStr | Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients |
title_full_unstemmed | Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients |
title_short | Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients |
title_sort | apolipoprotein e imbalance in the cerebrospinal fluid of alzheimer’s disease patients |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628034/ https://www.ncbi.nlm.nih.gov/pubmed/36324176 http://dx.doi.org/10.1186/s13195-022-01108-2 |
work_keys_str_mv | AT lennolmatthewpaul apolipoproteineimbalanceinthecerebrospinalfluidofalzheimersdiseasepatients AT sanchezdominguezirene apolipoproteineimbalanceinthecerebrospinalfluidofalzheimersdiseasepatients AT cuchilloibanezinmaculada apolipoproteineimbalanceinthecerebrospinalfluidofalzheimersdiseasepatients AT camporesielena apolipoproteineimbalanceinthecerebrospinalfluidofalzheimersdiseasepatients AT brinkmalmgunnar apolipoproteineimbalanceinthecerebrospinalfluidofalzheimersdiseasepatients AT alcoleadaniel apolipoproteineimbalanceinthecerebrospinalfluidofalzheimersdiseasepatients AT forteajuan apolipoproteineimbalanceinthecerebrospinalfluidofalzheimersdiseasepatients AT lleoalberto apolipoproteineimbalanceinthecerebrospinalfluidofalzheimersdiseasepatients AT soriaguadalupe apolipoproteineimbalanceinthecerebrospinalfluidofalzheimersdiseasepatients AT aguadofernando apolipoproteineimbalanceinthecerebrospinalfluidofalzheimersdiseasepatients AT zetterberghenrik apolipoproteineimbalanceinthecerebrospinalfluidofalzheimersdiseasepatients AT blennowkaj apolipoproteineimbalanceinthecerebrospinalfluidofalzheimersdiseasepatients AT saezvalerojavier apolipoproteineimbalanceinthecerebrospinalfluidofalzheimersdiseasepatients |